Lieff Cabraser is investigating reports of widespread complaints from users of prenatal testing kits aimed at finding rare genetic disorders. According to the New York Times, positive results from over 80% of some tests aimed at finding evidence of genetic disorders have been found to be wrong. These extraordinarily high test failure rates have led families to terminate pregnancies that were actually viable and healthy.
“[Prospective parents] been misled by a wondrous promise that Silicon Valley has made to expectant mothers: that a few vials of their blood, drawn in the first trimester, can allow companies to detect serious developmental problems in the DNA of the fetus with remarkable accuracy…. The grave predictions made by those newer tests are usually wrong, The New York Times has found.”
The Times article further observes, “Nonetheless, on product brochures and test result sheets, companies describe the tests to pregnant women and their doctors as near certain. They advertise their findings as ‘reliable’ and ‘highly accurate,’ offering ‘total confidence’ and ‘peace of mind’ for patients who want to know as much as possible.”
The prenatal testing companies involved include Natera, Myriad Genetics, Labcorp, Sequenom, Roche, and Quest.
If you have used Noninvasive Prenatal Genetic Testing (NIPT) to find dangerous genetic markers in embryo samples, we urge you to contact a consumer protection lawyer at Lieff Cabraser today about your potential case and recovery. Any information you provide will be held in the strictest confidence, and will help us hold prenatal testing companies accountable for all false and misleading advertising as well as the failed test results.